Table 1 Clinical characteristics, lung function and laboratory measurements
Non-COPD | COPD | |
|---|---|---|
Age, years | 57.3 ± 7.2 | 58.5 ± 5.8 |
Male sex, n (%) | 9 (64.2%) | 24 (96%) |
Body mass index (Kg/m2) | 24.6 ± 1.7 | 25.4 ± 2.8 |
Never smoked, % | 5 (35.7%) | 0 (0%) |
Current smokers, % | 6 (43%) | 17 (68%) |
Ex-smokers, % | 3 (21%) | 8 (32%) |
Smoking history, pack-years | 38.6 ± 22.4 | 60.1 ± 33.9 |
Expiratory carbon monoxide, ppm | 1.5 ± 1.5 | 2.4 ± 2.2 |
FEV1, % predicted | 91.7 ± 10.5 | 56.7 ± 21.5*** |
FEV1/FVC, % | 76.2 ± 4.5 | 51.0 ± 14.7*** |
TLC, % predicted | 90.9 ± 14.5 | 106.6 ± 17.3* |
RV, % predicted | 108.8 ± 20.8 | 164.4 ± 69.2** |
DLCO, % predicted | 82.5 ± 11.9 | 63.4 ± 20.1** |
PaO2, mmHg | 85.0 ± 12.8 | 75.3 ± 10.5 * |
PaCO2, mmHg | 37.3 ± 2.8 | 37.3 ± 3.8 |
Total cholesterol, mg/dL | 196.0 ± 31.4 | 203.2 ± 39.5 |
Triglycerides, mg/dL | 92.4 ± 25.0 | 111.2 ± 46.7 |
HDL, mg/dL | 47.0 ± 12.3 | 48.6 ± 12.1 |
LDL mg/dL | 129.4 ± 28.0 | 132.4 ± 34.0 |
Framingham risk score$ | 8.4 ± 4.8 | 10.9 ± 5.7 |
Glucose, mg/dL | 97.1 ± 10.3 | 100.7 ± 20.5 |
Leukocyte count, × 109/L | 7.7 ± 1.7 | 8.4 ± 1.5 |
Lymphocyte count, × 109/L | 1.6 ± 0.5 | 1.8 ± 0.4 |
Monocyte count, × 109/L | 0.4 ± 0.1 | 0.4 ± 0.1 |
Neutrophils, ×109/L | 5.2 ± 1.5 | 5.7 ± 1.4 |
Red blood cells, × 1012/L | 4.6 ± 0.4 | 4.6 ± 0.3 |
Haemoglobin, g/L | 137.0 ± 13.2 | 146.5 ± 9.3* |
Platelet count, × 109/L | 309.5 ± 88.0 | 252.2 ± 61.0* |
C-reactive protein, mg/L | 1.1 ± 1.5 | 1.0 ± 2.1 |
Fibrinogen, mg/L | 5.4 ± 1.9 | 4.0 ± 1.2 |
Nitrites/nitrates, nMol/mL | 20.4 ± 7.0 | 22.4 ± 10.6 |
Endothelin-1, pmol/L | 6.5 ± 4.3 | 5.8 ± 2.3 |
Angiopoietin-2, pg/mL | 527.0 ± 99.6 | 433.3 ± 142.0 |
VEGF, pg/mL | 49.8 ± 41.0 | 57.8 ± 78.7 |
VEGFR2, pg/mL | 34.4 ± 10.4 | 53.7 ± 7.8 |
IL-6, pg/mL | 5 ± 7.2 | 7.7 ± 16.0 |
BNP. pg/mL | 15.9 ± 6.2 | 21.8 ± 18.2 |